Abstract:Background: Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight, fostering investigation of GLP1RA for the treatment of obesity. Scope of review: Here I discuss the physiology of Glucagon-like peptide-1 (GLP-1) action in the control of food intake in animals and humans, highlighting the importance of gut vs. brain-derived GLP-1 for the control of feeding and body weight. The widespread distribution and function of multiple GLP-1 receptor (GLP1R) populations in the central and autonomic nervous system are outlined, and the importance of pathways controlling energy expenditure in preclinical studies vs. reduction of food intake in both animals and humans is highlighted. The relative contributions of vagal afferent pathways vs. GLP1R+ populations in the central nervous system for the physiological reduction of food intake and the anorectic response to GLP1RA are compared and reviewed. Key data enabling the development of two GLP1RA for obesity therapy (liraglutide 3 mg daily and semaglutide 2.4 mg once weekly) are discussed. Finally, emerging data potentially supporting the combination of GLP-1 with additional peptide epitopes in unimolecular multi-agonists, as well as in fixed-dose combination therapies, are highlighted. Major conclusions: The actions of GLP-1 to reduce food intake and body weight are highly conserved in obese animals and humans, in both adolescents and adults. The well-defined mechanisms of GLP-1 action through a single G protein-coupled receptor, together with the extensive safety database of GLP1RA in people with T2D, provide reassurance surrounding the long-term use of these agents in people with obesity and multiple co-morbidities. GLP1RA may also be effective in conditions associated with obesity, such as cardiovascular disease and non-alcoholic steatohepatitis (NASH). Progressive improvements in the efficacy of GLP1RA suggest that GLP-1-based therapies may soon rival bariatric surgery as viable options for the treatment of obesity and its complications.

Are GLP-1R agonists the long-sought-after panacea for obesity?

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

GLP-1 physiology informs the pharmacotherapy of obesity

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

GLP-1 and Amylin in the Treatment of Obesity

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity

Investigational glucagon-like peptide-1 agonists for the treatment of obesity

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

The incretin/glucagon system as a target for pharmacotherapy of obesity

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review